Treatment with polatuzumab vedotin, obinutuzumab, and venecolax, shows promise in the response rates at end of induction in patients with RR FL.
Among patients with FL, approximately what percentage are reported as having activating mutations of EZH2?
Tazemetostat yielded durable responses and was generally well tolerated in a recent study of heavily pretreated patients with relapse or refractory follicular lymphoma (FL; Lancet Oncol. 2020 Oct 6.…
Long-term follow-up results from the FoRT study shows that the optimal RT dose for patients with indolent NHL is _________.
Fill in the Blank: Long-term follow-up results from the FoRT study show that the optimal radiotherapy dose to treat patients with indolent non-Hodgkin lymphoma is ___ Gy in ___ fractions, according…
Long-term follow-up from the FoRT study shows that the optimal RT dose for patients with indolent NHL and histologic FL or MZL is 24 Gy in 12 fractions.
Study findings lead experts to suggest that the prevalence of DLBCL and FL will likely rise in the United States and Europe, according to research presented at the NCCN Annual Conference.
True or false: The FDA has approved tazemetostat for the treatment of patients with confirmed EZH2-positive relapsed/refractory FL.
The FDA granted accelerated approval to umbralisib for the treatment of adults with relapsed/refractory FL or MZL.